Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.

Pan MR, Wu CC, Kan JY, Li QL, Chang SJ, Wu CC, Li CL, Ou-Yang F, Hou MF, Yip HK, Luo CW.

Cancers (Basel). 2019 Dec 30;12(1). pii: E94. doi: 10.3390/cancers12010094.

2.

Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer.

Tsai HL, Pang SY, Wang HC, Luo CW, Li QL, Chen TY, Fang SY, Wang JY, Pan MR.

Am J Cancer Res. 2019 Nov 1;9(11):2544-2553. eCollection 2019.

3.

Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.

Ou-Yang F, Pan MR, Chang SJ, Wu CC, Fang SY, Li CL, Hou MF, Luo CW.

Life Sci. 2019 Dec 1;238:116963. doi: 10.1016/j.lfs.2019.116963. Epub 2019 Oct 19.

PMID:
31639396
4.

Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy.

Wang HC, Chou CL, Yang CC, Huang WL, Hsu YC, Luo CW, Chen TJ, Li CF, Pan MR.

Int J Mol Sci. 2019 Aug 21;20(17). pii: E4087. doi: 10.3390/ijms20174087.

5.

Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer.

Hsu MC, Tsai YL, Lin CH, Pan MR, Shan YS, Cheng TY, Cheng SH, Chen LT, Hung WC.

J Hematol Oncol. 2019 Jul 19;12(1):79. doi: 10.1186/s13045-019-0769-7.

6.

Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication.

Hung YH, Hsu MC, Chen LT, Hung WC, Pan MR.

J Clin Med. 2019 Jun 24;8(6). pii: E903. doi: 10.3390/jcm8060903. Review.

7.

Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.

Hsu MC, Pan MR, Hung WC.

Cells. 2019 Mar 21;8(3). pii: E270. doi: 10.3390/cells8030270. Review.

8.

FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer.

Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, Yip HK, Luo CW.

J Clin Med. 2019 Jan 2;8(1). pii: E38. doi: 10.3390/jcm8010038.

9.

Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression.

Hsu MC, Pan MR, Chu PY, Tsai YL, Tsai CH, Shan YS, Chen LT, Hung WC.

Cancers (Basel). 2018 Dec 20;11(1). pii: E8. doi: 10.3390/cancers11010008.

10.

From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis.

Wang HC, Hung WC, Chen LT, Pan MR.

Int J Mol Sci. 2018 Nov 13;19(11). pii: E3584. doi: 10.3390/ijms19113584. Review.

11.

Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.

Tian YF, Wang HC, Luo CW, Hung WC, Lin YH, Chen TY, Li CF, Lin CY, Pan MR.

Am J Cancer Res. 2018 Sep 1;8(9):1812-1822. eCollection 2018.

12.

Cell Motility Facilitated by Mono(2-ethylhexyl) Phthalate via Activation of the AKT-β-Catenin-IL-8 Axis in Colorectal Cancer.

Luo CW, Hsiao IL, Wang JY, Wu CC, Hung WC, Lin YH, Chen TY, Hsu YC, Cheng TL, Pan MR.

J Agric Food Chem. 2018 Sep 19;66(37):9635-9644. doi: 10.1021/acs.jafc.8b03558. Epub 2018 Sep 6.

PMID:
30188700
13.

CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.

Luo CW, Wu CC, Chang SJ, Chang TM, Chen TY, Chai CY, Chang CL, Hou MF, Pan MR.

Exp Cell Res. 2018 Feb 1;363(1):65-72. doi: 10.1016/j.yexcr.2017.12.032. Epub 2018 Jan 3.

PMID:
29305962
14.

The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.

Hou MF, Luo CW, Chang TM, Hung WC, Chen TY, Tsai YL, Chai CY, Pan MR.

Exp Cell Res. 2017 Oct 15;359(2):458-465. doi: 10.1016/j.yexcr.2017.08.029. Epub 2017 Aug 24.

PMID:
28842166
15.

Orchestration of H3K27 methylation: mechanisms and therapeutic implication.

Pan MR, Hsu MC, Chen LT, Hung WC.

Cell Mol Life Sci. 2018 Jan;75(2):209-223. doi: 10.1007/s00018-017-2596-8. Epub 2017 Jul 17. Review.

16.

CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor.

Wu CC, Pan MR, Wei YC, Lin CH, Yang SF, Tsai HP, Luo CW, Chai CY.

Appl Immunohistochem Mol Morphol. 2018 Nov/Dec;26(10):775-780. doi: 10.1097/PAI.0000000000000522.

PMID:
28549031
17.

G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response.

Luo CW, Wang JY, Hung WC, Peng G, Tsai YL, Chang TM, Chai CY, Lin CH, Pan MR.

Radiother Oncol. 2017 Sep;124(3):395-402. doi: 10.1016/j.radonc.2017.03.002. Epub 2017 Mar 25.

PMID:
28351524
18.

β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer.

Yin HL, Wu CC, Lin CH, Chai CY, Hou MF, Chang SJ, Tsai HP, Hung WC, Pan MR, Luo CW.

Int J Mol Sci. 2016 Aug 31;17(9). pii: E1432. doi: 10.3390/ijms17091432.

19.

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.

Pan MR, Hsu MC, Luo CW, Chen LT, Shan YS, Hung WC.

Oncotarget. 2016 Sep 20;7(38):61136-61151. doi: 10.18632/oncotarget.11256.

20.

Connecting the Dots: From DNA Damage and Repair to Aging.

Pan MR, Li K, Lin SY, Hung WC.

Int J Mol Sci. 2016 May 6;17(5). pii: E685. doi: 10.3390/ijms17050685. Review.

Supplemental Content

Loading ...
Support Center